TY  - JOUR
A1  - Klein, Philipp
A1  - Barthels, Fabian
A1  - Johe, Patrick
A1  - Wagner, Annika
A1  - Tenzer, Stefan
A1  - Distler, Ute
A1  - Le, Thien Anh
A1  - Schmid, Paul
A1  - Engel, Volker
A1  - Engels, Bernd
A1  - Hellmich, Ute A.
A1  - Opatz, Till
A1  - Schirmeister, Tanja
T1  - Naphthoquinones as covalent reversible inhibitors of cysteine proteases — studies on inhibition mechanism and kinetics
JF  - Molecules
N2  - The facile synthesis and detailed investigation of a class of highly potent protease inhibitors based on 1,4-naphthoquinones with a dipeptidic recognition motif (HN-l-Phe-l-Leu-OR) in the 2-position and an electron-withdrawing group (EWG) in the 3-position is presented. One of the compound representatives, namely the acid with EWG = CN and with R = H proved to be a highly potent rhodesain inhibitor with nanomolar affinity. The respective benzyl ester (R = Bn) was found to be hydrolyzed by the target enzyme itself yielding the free acid. Detailed kinetic and mass spectrometry studies revealed a reversible covalent binding mode. Theoretical calculations with different density functionals (DFT) as well as wavefunction-based approaches were performed to elucidate the mode of action.
KW  - protease
KW  - rhodesain
KW  - covalent reversible inhibition
KW  - 1,4-naphthoquinone
KW  - nucleophilic addition
KW  - prodrug
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-203791
SN  - 1420-3049
VL  - 25
IS  - 9
ER  - 
TY  - RPRT
A1  - Angnide, Enarile
A1  - Bielitska, Iryna
A1  - Borchert, Leon
A1  - Braun, Louisa
A1  - Bühler, Pascal
A1  - Chen, Xinyue
A1  - Ho, Katherina
A1  - Hofmann, Lena
A1  - Kebekus, Melvin
A1  - Kubsch, Torbjörn
A1  - Li, Alexander
A1  - Lin, Simon
A1  - Mischer, Andreas
A1  - Mogus, Mateja
A1  - Schmid, Fabian
A1  - Schneidawind, Luisa
A1  - Voss, Manuela
A1  - Wilson, Claire
A1  - Wieteska, Filip
A1  - Yu, Linda
ED  - Lindner, Jonas
ED  - Fischer, Doris
T1  - Chinese Entanglements in Lower Franconian Business
BT  - A student research project by the Chair of China Business and Economics at the University of Würzburg
N2  - Using own survey data and interviews, this study analyzes how businesses in Lower Franconia (Unterfranken) are entangled with China. Starting with a bird's-eye-view of the current situation, the study goes on to provide valuable insights from five specific industries. The study shows that a majority of the analyzed firms have some sort of ties to China, be it through Chinese customers, import/export activities, or else.
KW  - China
KW  - Unterfranken
KW  - China
KW  - Lower Franconia
KW  - Unterfranken
KW  - business
KW  - entanglement
KW  - Handel
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-209876
ER  - 
TY  - JOUR
A1  - Hanitsch, Leif
A1  - Baumann, Ulrich
A1  - Boztug, Kaan
A1  - Burkhard‐Meier, Ulrike
A1  - Fasshauer, Maria
A1  - Habermehl, Pirmin
A1  - Hauck, Fabian
A1  - Klock, Gerd
A1  - Liese, Johannes
A1  - Meyer, Oliver
A1  - Müller, Rainer
A1  - Pachlopnik‐Schmid, Jana
A1  - Pfeiffer‐Kascha, Dorothea
A1  - Warnatz, Klaus
A1  - Wehr, Claudia
A1  - Wittke, Kirsten
A1  - Niehues, Tim
A1  - von Bernuth, Horst
T1  - Treatment and management of primary antibody deficiency: German interdisciplinary evidence‐based consensus guideline
JF  - European Journal of Immunology
N2  - This evidence‐based clinical guideline provides consensus‐recommendations for the treatment and care of patients with primary antibody deficiencies (PADs). The guideline group comprised 20 clinical and scientific expert associations of the German, Swiss, and Austrian healthcare system and representatives of patients. Recommendations were based on results of a systematic literature search, data extraction, and evaluation of methodology and study quality in combination with the clinical expertise of the respective representatives. Consensus‐based recommendations were determined via nominal group technique. PADs are the largest clinically relevant group of primary immunodeficiencies. Most patients with PADs present with increased susceptibility to infections, however immune dysregulation, autoimmunity, and cancer affect a significant number of patients and may precede infections. This guideline therefore covers interdisciplinary clinical and therapeutic aspects of infectious (e.g., antibiotic prophylaxis, management of bronchiectasis) and non‐infectious manifestations (e.g., management of granulomatous disease, immune cytopenia). PADs are grouped into disease entities with definitive, probable, possible, or unlikely benefit of IgG‐replacement therapy. Summary and consensus‐recommendations are provided for treatment indication, dosing, routes of administration, and adverse events of IgG‐replacement therapy. Special aspects of concomitant impaired T‐cell function are highlighted as well as clinical data on selected monogenetic inborn errors of immunity formerly classified into PADs (APDS, CTLA‐4‐, and LRBA‐deficiency).
KW  - autoimmunity
KW  - CVID
KW  - hypogammaglobulinemia
KW  - immunoglobulins
KW  - primary antibody deficiency
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225731
VL  - 50
IS  - 10
SP  - 1432
EP  - 1446
ER  -